Evidence map›Paper›PMID 42291429›Full record

ReviewPeerJ2026

Ivy Yee Yen Chew, Jaime Jacqueline Jayapalan, Jasmine Lim

Abstract readReview
In one paragraph

Review in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ivy Yee Yen ChewDepartment of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia.
Jaime Jacqueline JayapalanDepartment of Molecular Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia.
Jasmine LimDepartment of Surgery, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Wilayah Persekutuan, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is among the most common malignancies in men. Liquid biopsies enable repeated sampling of tumor-derived material, including extracellular vesicles (EVs) that provide stable, multianalyte molecular readouts. Expressed prostatic secretion (EPS), obtained directly or as EPS-urine after prostate massage, is an organ-proximal matrix enriched in prostate-derived proteins, metabolites, and prostasome-like EVs, but its use is limited by low volumes, urine dilution, and lack of standardized protocols. Glycosylation, is a non-templated post-translational modification regulated by enzyme networks and nucleotide-sugar availability, allowing glycomic phenotypes to capture disease states beyond gene or protein levels. This review covers studies from 1985 to 2025 on EPS-associated glycosylation in PCa and, despite limited and heterogenous data, consistently reports altered core fucosylation, terminal sialylation, and

Indexed as

Biomarkers, TumorProstateProstatic NeoplasmsDisease ProgressionExtracellular VesiclesGlycomicsGlycosylationHumansLiquid BiopsyMalePolysaccharidesBiomarkers, TumorPolysaccharidesBiomarkersExpressed prostatic secretions (EPS)Extracellular vesicles (EV)GlycomicsGlycosylationLiquid biopsyProstate cancer

Identifiers

PMID42291429
PMCPMC13262545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.